SCHEMBL2129888

SCHEMBL2129888

C=Cc1cccc2cccnc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.54
MAPT P10636 4/20 0.54
LMNA P02545 3/20 0.54
TDP1 Q9NUW8 3/20 0.54
MMP2 P08253 2/20 0.54
TSHR P16473 2/20 0.54
NFKB1 P19838 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
GMNN O75496 1/20 0.54
TP53 P04637 1/20 0.54
HSP90AA1 P07900 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
MMP9 P14780 1/20 0.54
ALOX15 P16050 1/20 0.54
MMP8 P22894 1/20 0.54
CCR1 P32246 1/20 0.54
THPO P40225 1/20 0.54
MTOR P42345 1/20 0.54
HTT P42858 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3243930 0.84 KDM4E (0.50) KDM4EMAPTLMNATDP1MMP2
SCHEMBL6847746 0.80 KDM4E (0.50) KDM4EMAPTLMNATDP1MMP2
SCHEMBL6850791 0.80 KDM4E (0.50) KDM4EMAPTLMNATDP1MMP2
SCHEMBL216372 0.79 KDM4E (0.54) KDM4EMAPTLMNATDP1MMP2
SCHEMBL194281 0.79 KDM4E (0.54) KDM4EMAPTLMNATDP1MMP2
SCHEMBL24060233 0.79 KDM4E (0.54) KDM4EMAPTLMNATDP1MMP2
SCHEMBL16309644 0.79 KDM4E (0.48) KDM4EMAPTLMNATDP1MMP2
SCHEMBL20726958 0.79 LMNA (0.55) KDM4EMAPTLMNATDP1MMP2
SCHEMBL23519813 0.79 KDM4E (0.54) KDM4EMAPTLMNATDP1MMP2
SCHEMBL26115261 0.79 KDM4E (0.43) KDM4EMAPTLMNATDP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9562116-B2 Method for preparation of ruthenium-based metathesis catalysts with chelating alkylidene ligands UMICORE AG & CO. KG (DE) 2017-02-07 US claimed
CN-102481557-B Method for preparation of ruthenium-based metathesis catalysts with chelating alkylidene ligands UMICORE AG & CO KG 2015-04-01 CN claimed
US-20140371462-A1 METHOD FOR PREPARATION OF RUTHENIUM-BASED METATHESIS CATALYSTS WITH CHELATING ALKYLIDENE LIGANDS UMICORE AG & CO KG (DE) 2014-12-18 US claimed
US-8846938-B2 Method for preparation of ruthenium-based metathesis catalysts with chelating alkylidene ligands UMICORE AG & CO. KG (DE) 2014-09-30 US claimed
EP-2255877-B1 Method for preparation of ruthenium-based metathesis catalysts with chelating alkylidene ligands UMICORE AG & CO KG (DE) 2014-09-24 EP claimed
US-8658796-B2 Complexes of ruthenium, method of production thereof and use thereof as (pre)catalysts of the metathesis reaction UMICORE AG & CO. KG (DE) 2014-02-25 US claimed
US-20130079515-A1 Complexes of Ruthenium, Method of Production Thereof And Use Thereof As (Pre)Catalysts of the Metathesis Reaction UMICORE AG & CO. KG (DE) 2013-03-28 US claimed
US-8318965-B2 Complex of ruthenium, method of production thereof and use thereof as (pre)catalysts of the metathesis reaction UMICORE AG & CO. KG (DE) 2012-11-27 US claimed
EP-2029278-B1 COMPLEX OF RUTHENIUM, METHOD OF PRODUCTION THEREOF AND USE THEREOF AS (PRE)CATALYST OF THE METATHESIS REACTION UMICORE AG & CO KG (DE) 2012-10-24 EP claimed
CN-102481557-A Process for preparing ruthenium-based metathesis catalysts with chelating alkylidene ligands UMICORE AG & CO KG 2012-05-30 CN claimed
US-20120101279-A1 METHOD FOR PREPARATION OF RUTHENIUM-BASED METATHESIS CATALYSTS WITH CHELATING ALKYLIDENE LIGANDS UMICORE AG & CO. KG (DE) 2012-04-26 US claimed
EP-2255877-A1 Method for preparation of ruthenium-based metathesis catalysts with chelating alkylidene ligands Umicore AG & Co. KG (DE) 2010-12-01 EP claimed
WO-2010127829-A1 METHOD FOR PREPARATION OF RUTHENIUM-BASED METATHESIS CATALYSTS WITH CHELATING ALKYLIDENE LIGANDS UMICORE AG & CO. KG (DE) 2010-11-11 WO claimed
US-20250177965-A1 HETEROGENEOUS CATALYSTS AND METHODS MAKING AND USING THEREOF THE UNIVERSITY OF HONG KONG (CN) 2025-06-05 US disclosed
CN-120054643-A Heterogeneous catalysts and methods of making and using the same 香港大学 2025-05-30 CN disclosed
US-20250122133-A1 Selective Transition Metal Catalyzed Deuterium Incorporation Into Alkyne and Alkene Functionalities MARQUETTE UNIVERSITY 2025-04-17 US disclosed
WO-2008000644-A1 NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METAHESIS REACTIONS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed
CN-1100414-A Preparation of pharmaceutical compound containing novel derivative of leukol SMITHKLINE BECKMAN INTERCREDIT (NL) 1995-03-22 CN disclosed
CN-1027368-C Process for preparing substituted quinoline derivatives SMITHKLINE BECKMAN INTERCREDIT (NL) 1995-01-11 CN disclosed
CN-1035501-A PROCESS FOR PREPARING SUBSTITUTED QUINOLINE DERIVATIVES SMITHKLINE BECKMAN INTERCREDIT (NL) 1989-09-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122133-A1 Selective Transition Metal Catalyzed Deuterium Incorporation Into Alkyne and Alkene Functionalities HDHD5, DDT, AHR KDM4E 2682/4885MAPT 4366/4885LMNA 2028/4885
US-20120101279-A1 METHOD FOR PREPARATION OF RUTHENIUM-BASED METATHESIS CATALYSTS WITH CHELATING ALKYLIDENE LIGANDS HMOX2, TIMCC, HPD KDM4E 2430/4885MAPT 4290/4885LMNA 2907/4885
US-20130079515-A1 Complexes of Ruthenium, Method of Production Thereof And Use Thereof As (Pre)Catalysts of the Metathesis Reaction CBR3, CBR1, C1R KDM4E 2452/4885MAPT 4787/4885LMNA 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.